BEN-GAY ICE 2.5 %
MENTHOL : 2.5 % · DIN 02230265 · PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION
Health Canada status: CANCELLED POST MARKET
What is BEN-GAY ICE?
BEN-GAY ICE 2.5 % contains MENTHOL : 2.5 %. It is listed in the Health Canada Drug Product Database under DIN 02230265, held by PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION, supplied as GEL for TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Aug-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is BEN-GAY ICE called?
Also recorded in Canada as: menthol 10 MG Oral Lozenge [Fisherman's Friend] (US), menthol 5 MG/ML Oral Cream [Canker Complete] (US), dyclonine hydrochloride 3 MG / menthol 6 MG Oral Lozenge [Sucrets Complete] (US), benzocaine 200 MG/ML / menthol 5 MG/ML Topical Spray [Little Ouchies] (US), menthol 80 MG/ML Topical Spray [Stopain] (US), camphor 0.09 MG/MG / menthol 0.013 MG/MG Topical Ointment [Mentholatum] (US), menthol 0.031 MG/MG Topical Gel [Perform] (US), menthol 100 MG/ML Topical Spray [Biofreeze] (US), menthol 0.035 MG/MG Topical Gel [Biofreeze] (US), capsaicin 0.00025 MG/MG / menthol 0.1 MG/MG Topical Gel [Capzasin Quick Relief] (US), menthol 2.5 MG Oral Lozenge [Luden's] (US), benzocaine 6 MG / dextromethorphan hydrobromide 5 MG / menthol 10 MG Oral Lozenge [Chloraseptic Sore Throat + Cough] (US), benzocaine 15 MG / menthol 10 MG Oral Lozenge [Chloraseptic Sore Throat] (US), menthol 12.5 MG/ML Topical Cream [Celadrin] (US), camphor 0.01 MG/MG / menthol 0.0054 MG/MG / petrolatum 0.98 MG/MG Topical Ointment [Boroleum] (US).
Product details and regulatory record
| DIN | 02230265 |
|---|---|
| Brand name | BEN-GAY ICE |
| Generic / active ingredient | MENTHOL : 2.5 % |
| Manufacturer | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION |
| Strength | 2.5 % |
| Dosage form | GEL |
| Route of administration | TOPICAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | M02AX10 VARIOUS |
| AHFS class | 08:12.06.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Aug-2001 |
| Original market date | 1997-01-20 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02230265 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2230265 |
| Brand name | BEN-GAY ICE |
| Active ingredient / INN | MENTHOL : 2.5 % |
| ATC code | M02AX10 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M02 |
| AHFS class | 08:12.06.08 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION |
Which pack is which?
| Strength on the label | 2.5 % |
|---|---|
| Dosage form | GEL |
| Route | TOPICAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code M02AX10 VARIOUS. 0 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABSORBINE JR EXTRA STRENGTH LINIMENT | 0.5 % | LIQUID | BRIDGES CONSUMER HEALTHCARE LLC | CANCELLED POST MARKET | DIN 01942271 |
| ABSORBINE JR LINIMENT | 1.25 % | SOLUTION | BRIDGES CONSUMER HEALTHCARE LLC | CANCELLED POST MARKET | DIN 01942301 |
| ABSORBINE POWER GEL | 4 % | GEL | W.F. YOUNG, INC. | DORMANT | DIN 01999524 |
| ANTIPHLOGISTINE RUB A-535 ICE GEL 4% | 4 % | GEL | CARTER PRODUCTS, DIVISION OF CARTER WALLACE NS INC. | CANCELLED POST MARKET | DIN 02034417 |
| ARTHRO RHEUMA CREAM | 1.5 % | CREAM | NATURLAND LTD. | CANCELLED POST MARKET | DIN 02240103 |
| ARTIC ICE ANALGESIC GEL 2.5% | 2.5 % | GEL | SCOTT CHEMICAL CANADA | CANCELLED POST MARKET | DIN 01915126 |
| BALMINIL CAMPHORUB | 6.5 % | OINTMENT | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 02233025 |
| BENGAY EXTRA STRENGTH ICE | 100 MG | CREAM | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED POST MARKET | DIN 02241251 |
| BIOFREEZE | 0.2 % | GEL | PERFORMANCE HEALTH INC. | CANCELLED POST MARKET | DIN 02237710 |
| BLUE ICE 2.5% | 2.5 % | GEL | LABORATOIRES DELON (1990) INC | CANCELLED POST MARKET | DIN 02244600 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.